CEBP Focus: Biomarkers and Biospecimens

Authors' A Vanderbilt Center, Na Departmen Tennessee Medical U Epidemiolo Correspon bilt Univers Nashville, T E-mail: Xia

[1]  R. DuBois,et al.  The role of COX-2 in intestinal inflammation and colorectal cancer , 2010, Oncogene.

[2]  N. Rothman,et al.  Urinary Prostaglandin E2 Metabolite and Gastric Cancer Risk in the Shanghai Women's Health Study , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[3]  N. Rothman,et al.  Oxidative stress, obesity, and breast cancer risk: results from the Shanghai Women's Health Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Carmela Conte,et al.  Oxidative stress-related aging: A role for prostate cancer? , 2009, Biochimica et biophysica acta.

[5]  J. Morrow,et al.  Levels of Prostaglandin E Metabolite and Leukotriene E4 Are Increased in the Urine of Smokers: Evidence that Celecoxib Shunts Arachidonic Acid into the 5-Lipoxygenase Pathway , 2009, Cancer Prevention Research.

[6]  J. Morrow,et al.  A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[7]  Daniel F. Gudbjartsson,et al.  A variant associated with nicotine dependence, lung cancer and peripheral arterial disease , 2008, Nature.

[8]  J. Morrow,et al.  Quantification of F2-isoprostanes as a biomarker of oxidative stress , 2007, Nature Protocols.

[9]  N. Rothman,et al.  Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. D. Billheimer,et al.  Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  D. Gozal,et al.  Urinary F2-isoprostane metabolite levels in children with sleep-disordered breathing , 2006, Sleep and Breathing.

[12]  S. Sheps,et al.  Specific comorbidity risk adjustment was a better predictor of 5-year acute myocardial infarction mortality than general methods. , 2006, Journal of clinical epidemiology.

[13]  J. Morrow,et al.  F2-Isoprostanes as markers of oxidative stress in vivo: An overview , 2005, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[14]  J. Morrow,et al.  Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. , 2004, Analytical biochemistry.

[15]  K. O'Reilly,et al.  Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[16]  R. DuBois,et al.  Cyclooxygenase-2: a potential target in breast cancer. , 2004, Seminars in oncology.

[17]  J. Elias,et al.  Interleukin-13 and leukotrienes: an intersection of pathogenetic schema. , 2003, American journal of respiratory cell and molecular biology.

[18]  T. Montine,et al.  Improved assay for the quantification of the major urinary metabolite of the isoprostane 15-F(2t)-Isoprostane (8-iso-PGF(2alpha)) by a stable isotope dilution mass spectrometric assay. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[19]  L. Packer,et al.  Handbook of Antioxidants , 2001 .

[20]  G. Wennergren.  Inflammatory mediators in blood and urine. , 2000, Paediatric respiratory reviews.

[21]  J. Morrow,et al.  Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. , 2000, Free radical biology & medicine.

[22]  J. Drazen,et al.  The biology of 5-lipoxygenase: function, structure, and regulatory mechanisms. , 1999, Proceedings of the Association of American Physicians.

[23]  G. FitzGerald,et al.  Alcohol-induced generation of lipid peroxidation products in humans. , 1999, The Journal of clinical investigation.

[24]  J. Manson,et al.  Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[25]  J. Morrow,et al.  Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. , 1995, The New England journal of medicine.

[26]  B Rosner,et al.  Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. , 1992, American journal of epidemiology.

[27]  J. Morrow,et al.  A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Robert A. Lewis,et al.  Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. , 1990, The New England journal of medicine.

[29]  Barry Halliwell,et al.  Oxidative stress and cancer: have we moved forward? , 2007, The Biochemical journal.

[30]  C. Matthews,et al.  Reproducibility and validity of the Shanghai Men's Health Study physical activity questionnaire. , 2007, American journal of epidemiology.

[31]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.